Table 2.

Serum SMRP concentration (nmol/L) according to tumor morphology and stage

n (%)Mean ± SDMedian (range)
Mesothelioma1073.05 ± 5.61.42 (0.21-40.84)
Histology
    Epithelioid72 (67.3)3.72 ± 6.61.64 (0.21-40.84)
    Mixed7 (6.5)1.69 ± 0.71.79 (0.48-2.74)
    Sarcomatous10 (9.4)0.99 ± 0.61.02 (0.25-2.16)
    Desmoplastic3 (2.8)0.5 ± 0.30.49 (0.23-0.77)
    NOS*15 (14.0)2.37 ± 2.71.42 (0.42-10.32)
Stage
    I-II43 (40.2)2.24 ± 3.81.25 (0.23-25.10)
    III-IV45 (42.0)3.93 ± 7.41.51 (0.21-40.84)
    NOS*19 (17.8)2.83 ± 3.41.06 (0.35-10.32)
Lung cancer2151.05 ± 1.10.82 (0.10-11.84)
Histology
    SCLC5 (2.3)0.96 ± 0.50.88 (0.44-1.65)
    Adenocarcinomas104 (48.4)1.14 ± 1.40.84 (0.10-11.84)
    Squamous62 (28.8)0.81 ± 0.50.70 (0.10-2.15)
    NSCLC26 (12.1)0.97 ± 1.00.70 (0.16-5.37)
    NOS*18 (8.4)1.44 ± 1.00.99 (0.53-3.61)
Stage
    I-II43 (20.0)1.04 ± 0.80.85 (0.22-3.91)
    III-IV145 (67.4)1.06 ± 1.20.88 (0.10-11.84)
    NOS*27 (12.6)1.01 ± 0.70.79 (0.22-3.41)
BRD1300.76 ± 0.40.68 (0.12-2.47)
    Asbestosis12 (9.2)0.70 ± 0.40.69 (0.15-1.74)
    BRD, asbestos46 (35.4)0.75 ± 0.30.69 (0.20-1.58)
    BRD, no asbestos31 (23.9)0.72 ± 0.50.61 (0.20-2.17)
    COPD§25 (19.2)0.87 ± 0.50.70 (0.33-2.48)
    Others16 (12.3)0.81 ± 0.60.68 (0.12-1.83)
Controls2620.76 ± 0.40.66 (0.16-2.36)
    Healthy exposed203 (77.5)0.75 ± 0.40.64 (0.16-2.36)
    Other controls59 (22.5)0.81 ± 0.40.72 (0.20-2.18)
  • * Not otherwise specified.

  • Pleural plaques, asbestos-related pleural thickening.

  • Interstitial lung diseases, chronic pleuritis.

  • § Chronic obstructive pulmonary disease.

  • Pneumonia, tuberculosis, sarcoidosis, empyema, other benign non–asbestos-related lung and pleural disorders.

  • Blood donors or patients hospitalized for orthopedic traumatic injury or eye disease.